Pharmacokinetic and pharmacodynamic interactions of propafenone and cimetidine.
The pharmacokinetics and pharmacodynamics of the extensively metabolized antiarrhythmic agent propafenone were assessed alone and during concomitant administration of cimetidine. Twelve healthy subjects were given successively the following treatments: propafenone 225 mg q8h plus cimetidine placebo; cimetidine 400 mg q8h plus propafenone placebo; and propafenone 225 mg plus cimetidine 400 mg q8h. After a minimum of 5 days on each regimen, plasma drug concentrations and electrocardiogram conduction intervals were measured during a drug washout period. The maximum concentration of propafenone in plasma was 993 +/- 532 ng/mL when propafenone was given alone compared with 1230 +/- 591 ng/mL when propafenone was given with cimetidine (P = .0622). Differences in tmax, t1/2, and Cp ss did not approach statistical significance when propafenone alone was compared with propafenone plus cimetidine. When compared with cimetidine, propafenone significantly increased the PR interval from 161 +/- 5 msec to 192 +/- 6 msec (P less than .01) and the QRS duration from 89 +/- 3 msec to 98 +/- 4 msec (P less than .01). Combination therapy caused a modest additional increase in QRS duration to 103 +/- 3 msec (P less than .01). In conclusion, cimetidine caused small changes in propafenone pharmacokinetics and pharmacodynamics; but these changes are unlikely to be clinically important.
Pritchett
E L
EL
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710.
Smith
W M
WM
Kirsten
E B
EB
D000328:Adult; D002927:Cimetidine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D004347:Drug Interactions; D004562:Electrocardiography; D006801:Humans; D008297:Male; D011405:Propafenone / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D012083:Renin / Q000097:blood; D013997:Time Factors
D011405:Propafenone; D002927:Cimetidine; D012083:Renin